Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Cessation reduces impact of smoking on hearing loss in women

08 Oct 2020

While cigarette smoking increases the likelihood of hearing loss among women, this risk may diminish over time after quitting, a recent study has found.

The researchers conducted a prospective study on 81,505 women participating in the Nurses’ Health Study II. At study entry in 1991, 66.5 percent were never smokers, 22.4 percent were past smokers, and 11.1 percent were current smokers.  The primary outcome was self-reported moderate or worse hearing loss, assessed by the final follow-up in 2013.

Over 1,533,214 person-years of follow-up, 2,760 incident cases of hearing loss were documented. Smoking emerged as a significant risk factor, and its effect varied according to smoking intensity.

For example, among past smokers, those who had smoked for ≥20 pack-years (adjusted relative risk [RR], 1.30, 95 percent confidence interval [CI], 1.09–1.55) were at greater risk of hearing loss than counterparts who had smoked only 10–19 (adjusted RR, 1.32, 95 percent CI, 1.16–1.50) and <10 (adjusted RR, 1.10, 95 percent CI, 0.98–1.23) pack-years. The trend was statistically significant (p<0.001).

A similar pattern was reported for current smokers (ptrend=0.02), though the magnitude of the risk estimates were lower.

Notably, signals for the moderating effect of smoking cessation were observed, such that the risk of hearing loss in women decreased with increasing time since quitting, but this trend was of borderline significance (p=0.06).

“Cigarette smoking is a well-established risk factor for many adverse health outcomes, and these findings contribute to the body of evidence that supports the benefits of quitting smoking,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.